203 related articles for article (PubMed ID: 17082621)
1. The immunosuppressant cyclosporin A antagonizes human formyl peptide receptor through inhibition of cognate ligand binding.
Yan P; Nanamori M; Sun M; Zhou C; Cheng N; Li N; Zheng W; Xiao L; Xie X; Ye RD; Wang MW
J Immunol; 2006 Nov; 177(10):7050-8. PubMed ID: 17082621
[TBL] [Abstract][Full Text] [Related]
2. The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-DMet activates neutrophils preferentially through the lipoxin A(4) receptor.
Dahlgren C; Christophe T; Boulay F; Madianos PN; Rabiet MJ; Karlsson A
Blood; 2000 Mar; 95(5):1810-8. PubMed ID: 10688842
[TBL] [Abstract][Full Text] [Related]
3. The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1.
Stenfeldt AL; Karlsson J; Wennerås C; Bylund J; Fu H; Dahlgren C
Biochem Pharmacol; 2007 Oct; 74(7):1050-6. PubMed ID: 17692291
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporins: structure-activity relationships for the inhibition of the human FPR1 formylpeptide receptor.
Loor F; Tiberghien F; Wenandy T; Didier A; Traber R
J Med Chem; 2002 Oct; 45(21):4613-28. PubMed ID: 12361388
[TBL] [Abstract][Full Text] [Related]
5. The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met is a potent chemotactic agonist for mouse formyl peptide receptor.
He R; Tan L; Browning DD; Wang JM; Ye RD
J Immunol; 2000 Oct; 165(8):4598-605. PubMed ID: 11035102
[TBL] [Abstract][Full Text] [Related]
6. The peptide Trp-Lys-Tyr-Met-Val-D-Met activates neutrophils through the formyl peptide receptor only when signaling through the formylpeptide receptor like 1 is blocked. A receptor switch with implications for signal transduction studies with inhibitors and receptor antagonists.
Karlsson J; Fu H; Boulay F; Bylund J; Dahlgren C
Biochem Pharmacol; 2006 May; 71(10):1488-96. PubMed ID: 16549058
[TBL] [Abstract][Full Text] [Related]
7. Normal cell surface expression and selective loss of functions resulting from Phe110 to Ser and Cys126 to Trp substitutions in the formyl peptide receptor.
Nanamori M; He R; Sang H; Ye RD
Immunol Invest; 2004 May; 33(2):193-212. PubMed ID: 15195697
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition of human neutrophil activation by cyclosporins A, D, and H. Cyclosporin H is a potent and effective inhibitor of formyl peptide-induced superoxide formation.
Wenzel-Seifert K; Grünbaum L; Seifert R
J Immunol; 1991 Sep; 147(6):1940-6. PubMed ID: 1653806
[TBL] [Abstract][Full Text] [Related]
9. Differential activation of formyl peptide receptor signaling by peptide ligands.
Bae YS; Song JY; Kim Y; He R; Ye RD; Kwak JY; Suh PG; Ryu SH
Mol Pharmacol; 2003 Oct; 64(4):841-7. PubMed ID: 14500740
[TBL] [Abstract][Full Text] [Related]
10. Differential activation of formyl peptide receptor-like 1 by peptide ligands.
Bae YS; Yi HJ; Lee HY; Jo EJ; Kim JI; Lee TG; Ye RD; Kwak JY; Ryu SH
J Immunol; 2003 Dec; 171(12):6807-13. PubMed ID: 14662886
[TBL] [Abstract][Full Text] [Related]
11. Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation.
Le Y; Gong W; Li B; Dunlop NM; Shen W; Su SB; Ye RD; Wang JM
J Immunol; 1999 Dec; 163(12):6777-84. PubMed ID: 10586077
[TBL] [Abstract][Full Text] [Related]
12. The mechanism for activation of the neutrophil NADPH-oxidase by the peptides formyl-Met-Leu-Phe and Trp-Lys-Tyr-Met-Val-Met differs from that for interleukin-8.
Fu H; Bylund J; Karlsson A; Pellmé S; Dahlgren C
Immunology; 2004 Jun; 112(2):201-10. PubMed ID: 15147563
[TBL] [Abstract][Full Text] [Related]
13. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2.
Christophe T; Karlsson A; Dugave C; Rabiet MJ; Boulay F; Dahlgren C
J Biol Chem; 2001 Jun; 276(24):21585-93. PubMed ID: 11285256
[TBL] [Abstract][Full Text] [Related]
14. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling.
Bae YS; Lee HY; Jo EJ; Kim JI; Kang HK; Ye RD; Kwak JY; Ryu SH
J Immunol; 2004 Jul; 173(1):607-14. PubMed ID: 15210823
[TBL] [Abstract][Full Text] [Related]
15. 4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.
Kirpotina LN; Schepetkin IA; Khlebnikov AI; Ruban OI; Ge Y; Ye RD; Kominsky DJ; Quinn MT
Biochem Pharmacol; 2017 Oct; 142():120-132. PubMed ID: 28690139
[TBL] [Abstract][Full Text] [Related]
16. F2L, a peptide derived from heme-binding protein, inhibits formyl peptide receptor-mediated signaling.
Lee HY; Lee SY; Shin EH; Kim SD; Kim JM; Lee MS; Ryu SH; Bae YS
Biochem Biophys Res Commun; 2007 Aug; 359(4):985-90. PubMed ID: 17577578
[TBL] [Abstract][Full Text] [Related]
17. Microfluidic devices for characterizing the agonist of formyl peptide receptor in RBL-FPR cells.
Ye N; Wang MW; Qin J; Lin B
Biomed Microdevices; 2010 Jun; 12(3):513-21. PubMed ID: 20195765
[TBL] [Abstract][Full Text] [Related]
18. Functional expression of formyl peptide receptor family in human NK cells.
Kim SD; Kim JM; Jo SH; Lee HY; Lee SY; Shim JW; Seo SK; Yun J; Bae YS
J Immunol; 2009 Nov; 183(9):5511-7. PubMed ID: 19843937
[TBL] [Abstract][Full Text] [Related]
19. The endogenous opioid spinorphin blocks fMet-Leu-Phe-induced neutrophil chemotaxis by acting as a specific antagonist at the N-formylpeptide receptor subtype FPR.
Liang TS; Gao JL; Fatemi O; Lavigne M; Leto TL; Murphy PM
J Immunol; 2001 Dec; 167(11):6609-14. PubMed ID: 11714831
[TBL] [Abstract][Full Text] [Related]
20. Promotion of formyl peptide receptor 1-mediated neutrophil chemotactic migration by antimicrobial peptides isolated from the centipede Scolopendra subspinipes mutilans.
Park YJ; Lee SK; Jung YS; Lee M; Lee HY; Kim SD; Park JS; Koo J; Hwang JS; Bae YS
BMB Rep; 2016 Sep; 49(9):520-5. PubMed ID: 27502013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
